BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: Immunohistochemistry and public microarray data meta-analysis

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Pelekanou, Vassiliki ^a   Notas, George ^a   Kampa, Marilena ^a   Tsentelierou, Eleftheria ^a   Stathopoulos, Efstathios N ^a   Tsapis, Andreas ^a,b   Castanas, Elias ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER GRADING; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; VASCULAR ENDOTHELIUM;

B-CELL ACTIVATING FACTOR; B-CELL MATURATION ANTIGEN; CENTRAL NERVOUS SYSTEM NEOPLASMS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; NEOPLASM GRADING; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; TUMOR NECROSIS FACTORS;

EID: 84893394057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083250     Document Type: Article

References (93)

1. Kesari S (2011) Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments. Semin Oncol 38 Suppl 4: S2-10.
2. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, et al. (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215-225; discussion 226-219.
3. Rousseau A, Mokhtari K, Duyckaerts C (2008) The 2007 WHO classification of tumors of the central nervous system - what has changed? Curr Opin Neurol 21: 720-727.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
5. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173. (Pubitemid 43357943)
6. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, et al. (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69: 9065-9072.
7. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, et al. (2009) Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 69: 2091-2099.
8. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
9. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
10. Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27: 19-26. (Pubitemid 34131621)
11. Dillon SR, Gross JA, Ansell SM, Novak AJ (2006) An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5: 235-246. (Pubitemid 43336036)
12. Hatzoglou A, Roussel J, Bourgeade MF, Rogier E, Madry C, et al. (2000) TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 165: 1322-1330. (Pubitemid 30604561)
13. Notas G, Alexaki VI, Kampa M, Pelekanou V, Charalampopoulos I, et al. (2012) APRIL binding to BCMA activates a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest in liver cells. J Immunol 189: 4748-4758.
14. Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, et al. (2001) APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ 8: 403-410. (Pubitemid 32409611)
15. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, et al. (2002) Proinflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 299: 488-493. (Pubitemid 35365656)
16. Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC (2000) TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. J Immunol 164: 2897-2904. (Pubitemid 30148946)
17. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H (2000) Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 192: 1373-1380.
18. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, et al. (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272: 32401-32410. (Pubitemid 28011923)
19. Zhang JX, Ma HW, Sang M, Hu YS, Liang ZN, et al. (2010) Molecular structure, expression, cell and tissue distribution, immune evolution and cell proliferation of the gene encoding bovine (Bos taurus) TNFSF13 (APRIL). Dev Comp Immunol 34: 1199-1208.
20. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, et al. (2009) Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10: 778-785.
21. Benson MJ, Elgueta R, Noelle RJ (2008) B cell survival: an unexpected mechanism of lymphocyte vitality. Immunol Cell Biol 86: 485-486.
22. Zhang X, Park CS, Yoon SO, Li L, Hsu YM, et al. (2005) BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 17: 779-788. (Pubitemid 41417976)
23. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, et al. (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188: 1185-1190. (Pubitemid 28443341)
24. Shu HB, Hu WH, Johnson H (1999) TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 65: 680-683.
25. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, et al. (2002) DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3: 822-829.
26. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, et al. (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 172: 3268-3279. (Pubitemid 38263719)
27. He B, Raab-Traub N, Casali P, Cerutti A (2003) EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 171: 5215-5224. (Pubitemid 37432806)
28. Phillips TA, Ni J, Hunt JS (2003) Cell-specific expression of B lymphocyte (APRIL, BLyS)- and Th2 (CD30L/CD153)-promoting tumor necrosis factor superfamily ligands in human placentas. J Leukoc Biol 74: 81-87. (Pubitemid 38040439)
29. Deshayes F, Lapree G, Portier A, Richard Y, Pencalet P, et al. (2004) Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene 23: 3005-3012. (Pubitemid 38648191)
30. Alexaki VI, Notas G, Pelekanou V, Kampa M, Valkanou M, et al. (2009) Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development. J Immunol 183: 5948-5956.
31. Pelekanou V, Kampa M, Kafousi M, Darivianaki K, Sanidas E, et al. (2008) Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas. BMC Cancer 8: 76.
32. Sandberg WJ, Otterdal K, Gullestad L, Halvorsen B, Ragnarsson A, et al. (2009) The tumour necrosis factor superfamily ligand APRIL (TNFSF13) is released upon platelet activation and expressed in atherosclerosis. Thromb Haemost 102: 704-710.
33. Langat DL, Wheaton DA, Platt JS, Sifers T, Hunt JS (2008) Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta. Am J Pathol 172: 1303-1311. (Pubitemid 351671543)
34. Pelekanou V, Notas G, Theodoropoulou K, Kampa M, Takos D, et al. (2011) Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas. Anal Cell Pathol (Amst) 34: 49-60.
35. Sun B, Wang H, Wang X, Huang H, Ding W, et al. (2009) A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer. Exp Lung Res 35: 486-500.
36. Petty RD, Samuel LM, Murray GI, MacDonald G, O'Kelly T, et al. (2009) APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer 9: 434.
37. Alexaki VI, Pelekanou V, Notas G, Venihaki M, Kampa M, et al. (2012) B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies. Endocrinology 153: 739-749.
38. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195-200. (Pubitemid 40189428)
39. Tada S, Yasui T, Nakatsuji Y, Okuno T, Koda T, et al. (2013) BAFF Controls Neural Cell Survival through BAFF Receptor. PLoS One 8: e70924.
40. Thangarajh M, Masterman T, Hillert J, Moerk S, Jonsson R (2007) A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 65: 92-98. (Pubitemid 44968077)
41. Rousselet E, Traver S, Monnet Y, Perrin A, Mandjee N, et al. (2012) Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-alpha/epidermal growth factor receptor signaling pathway. Mol Pharmacol 82: 948-957.
42. Yepes M (2007) Tweak and FN14 in central nervous system health and disease. Front Biosci 12: 2772-2781.
43. Saas P, Boucraut J, Walker PR, Quiquerez AL, Billot M, et al. (2000) TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 32: 102-107.
44. Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, et al. (2002) TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 133: 116-123. (Pubitemid 35346733)
45. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, et al. (2003) The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 162: 1313-1321. (Pubitemid 36350675)
46. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, et al. (2005) The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 280: 3483-3492. (Pubitemid 40223813)
47. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, et al. (2004) Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 24: 8237-8244. (Pubitemid 39280803)
48. Polavarapu R, Gongora MC, Winkles JA, Yepes M (2005) Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. J Neurosci 25: 10094-10100. (Pubitemid 41636205)
49. Haile WB, Echeverry R, Wu F, Guzman J, An J, et al. (2010) Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience 171: 1256-1264.
50. Hamill CA, Michaelson JS, Hahm K, Burkly LC, Kessler JA (2007) Age-dependent effects of TWEAK/Fn14 receptor activation on neural progenitor cells. J Neurosci Res 85: 3535-3544. (Pubitemid 350228699)
51. Scholzke MN, Rottinger A, Murikinati S, Gehrig N, Leib C, et al. (2011) TWEAK regulates proliferation and differentiation of adult neural progenitor cells. Mol Cell Neurosci 46: 325-332.
52. Desplat-Jego S, Creidy R, Varriale S, Allaire N, Luo Y, et al. (2005) Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 117: 15-23. (Pubitemid 41725465)
53. Desplat-Jego S, Feuillet L, Creidy R, Malikova I, Rance R, et al. (2009) TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol 85: 132-135.
54. Serafini B, Magliozzi R, Rosicarelli B, Reynolds R, Zheng TS, et al. (2008) Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J Neuropathol Exp Neurol 67: 1137-1148.
55. Inta I, Frauenknecht K, Dorr H, Kohlhof P, Rabsilber T, et al. (2008) Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J Neurol Sci 275: 117-120.
56. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, et al. (2007) Molecular targets of glioma invasion. Cell Mol Life Sci 64: 458-478.
57. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, et al. (2006) Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 66: 9535-9542. (Pubitemid 44623652)
58. Killeen PR (2005) An alternative to null-hypothesis significance tests. Psychol Sci 16: 345-353.
59. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
60. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721. (Pubitemid 16237466)
61. Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, et al. (2006) Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 25: 5994-6002. (Pubitemid 44477293)
62. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, et al. (2005) Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 65: 8679-8689. (Pubitemid 41377355)
63. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, et al. (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024.
64. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102: 5814-5819. (Pubitemid 40559642)
65. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403. (Pubitemid 43668737)
66. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, et al. (2006) Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9: 287-300.
67. Montgomery SL, Bowers WJ (2012) Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol 7: 42-59.
68. McCoy MK, Ruhn KA, Martinez TN, McAlpine FE, Blesch A, et al. (2008) Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther 16: 1572-1579.
69. Hosomi N, Ban CR, Naya T, Takahashi T, Guo P, et al. (2005) Tumor necrosis factor-alpha neutralization reduced cerebral edema through inhibition of matrix metalloproteinase production after transient focal cerebral ischemia. J Cereb Blood Flow Metab 25: 959-967. (Pubitemid 41061711)
70. Paulino VM, Yang Z, Kloss J, Ennis MJ, Armstrong BA, et al. (2010) TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling. Mol Cancer Res 8: 1558-1567.
71. George-Chandy A, Trysberg E, Eriksson K (2008) Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 10: R97.
72. Ilzecka J, Ilzecki M (2006) APRIL is increased in serum of patients with brain glioblastoma multiforme. Eur Cytokine Netw 17: 276-280.
73. Kauer TM, Figueiredo JL, Hingtgen S, Shah K (2012) Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci 15: 197-204.
74. Kuijlen JM, Bremer E, Mooij JJ, den Dunnen WF, Helfrich W (2010) Review: on TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol 36: 168-182.
75. Oldenhuis CN, Stegehuis JH, Walenkamp AM, de Jong S, de Vries EG (2008) Targeting TRAIL death receptors. Curr Opin Pharmacol 8: 433-439.
76. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, et al. (2005) TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10: 233-243. (Pubitemid 40558131)
77. Hawkins CJ (2004) TRAIL and malignant glioma. Vitam Horm 67: 427-452.
78. Shah K, Tang Y, Breakefield X, Weissleder R (2003) Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 22: 6865-6872. (Pubitemid 37386686)
79. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H (1997) Role of gemistocytes in astrocytoma progression. Lab Invest 76: 277-284. (Pubitemid 27082071)
80. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, et al. (2009) Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res 29: 3269-3279.
81. Sabour Alaoui S, Dessirier V, de Araujo E, Alexaki VI, Pelekanou V, et al. (2012) TWEAK affects keratinocyte G2/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus. PLoS One 7: e33609.
82. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, et al. (1999) TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 274: 8455-8459. (Pubitemid 29164634)
83. Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, et al. (2002) Dual role for TWEAK in angiogenic regulation. J Cell Sci 115: 267-274. (Pubitemid 34145176)
84. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, et al. (2005) Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7: 7-16. (Pubitemid 40209466)
85. Wislet-Gendebien S, Wautier F, Leprince P, Rogister B (2005) Astrocytic and neuronal fate of mesenchymal stem cells expressing nestin. Brain Res Bull 68: 95-102. (Pubitemid 41698881)
86. Day ES, Cachero TG, Qian F, Sun Y, Wen D, et al. (2005) Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44: 1919-1931. (Pubitemid 40223621)
87. Yu G, Boone T, Delaney J, Hawkins N, Kelley M, et al. (2000) APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 1: 252-256.
88. Kargiotis O, Rao JS, Kyritsis AP (2006) Mechanisms of angiogenesis in gliomas. J Neurooncol 78: 281-293. (Pubitemid 44018823)
89. Maia S, Pelletier M, Ding J, Hsu YM, Sallan SE, et al. (2011) Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One 6: e20787.
90. Cols M, Barra CM, He B, Puga I, Xu W, et al. (2012) Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol 188: 6071-6083.
91. Kitange GJ, Templeton KL, Jenkins RB (2003) Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 15: 197-203. (Pubitemid 36735172)
92. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021. (Pubitemid 39331011)
93. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, et al. (2006) PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 51: 187-199. (Pubitemid 44063617)